Singapore, 12 July 2022: A novel therapy to treat rare gastrointestinal stromal tumours (GIST) has been accepted for evaluation by Singapore’s Health Sciences Authority.
QINLOCK® (ripretinib) now PBS listed for Australian patients QINLOCK is the first new reimbursed therapy to treat advanced GIST in more than a decade Leading Australian oncologist says the listing will help to “buy patients more time” Data shows QINLOCK reduces risk of disease progression by 85%1, 2 14 November, 2021: AUSTRALIAN cancer patients